if FDA expected early Q1 then why did Marjan say at AGM that US...

if FDA expected early Q1 then why did Marjan say at AGM that US launch expected in 2022? also UK launch a year away. I don't think current management plans to get SP to $1. I think Marjan and Smedley are planning to sell the company (maybe to Resmed) once SP hits .40/.50 since the bonus payment kicks in then. also no answer on who the institutional investors are? wouldn't it make sense to name them. don't know why the SP is so far below .20 at this point. is it because delayed FDA? I agree that $75m options for management is very excessive given they haven't delivered much so far. lots of unanswered questions like what happened to experiential studies, how many units has Cipla sold? IMO this is the reason why the SP is so low